Evidence map›Paper›PMID 25384064›Full record

ArticleJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2015

Postoperative radiotherapy is associated with better survival in non-small cell lung cancer with involved N2 lymph nodes: results of an analysis of the National Cancer Data Base.

John L Mikell, Theresa W Gillespie, William A Hall, Dana C Nickleach, Yuan Liu, Joseph Lipscomb, Suresh S Ramalingam, Raj S Rajpara, Seth D Force, Felix G Fernandez and 5 more

Registry-linked trialAbstract read
In one paragraph

Article in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06467383 (A Study to Describe the Diagnostic and Therapeutic Path of Patients with NSCLC in Early Stage and Locally Advanced), which is not on this map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06467383 recruitingnot on this mapstarted 2024, after this paper: background citation

A Study to Describe the Diagnostic and Therapeutic Path of Patients with NSCLC in Early Stage and Locally Advanced

TypeobservationalSponsorMSD Italia S.r.l.Ran2024 to 2025Enrolled600ConditionsNon-small Cell Lung Cancer, NSCLC, NSCLC, Stage III, NSCLC, Stage I
3 · Its place in the literature

Who cites it

53 citing papers in PubMed.

  1. Adaptive Neoadjuvant Chemotherapy Guided by (18)F-FDG PET in Resectable Non-Small Cell Lung Cancers: The NEOSCAN Trial.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2016
    Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Advances in multimodal treatment for stage IIIA-N2 non-small cell lung cancer.Journal of clinical and translational research · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

John L MikellDepartments of *Radiation Oncology, †Hematology and Oncology, ‡Surgery, §Biostatistics and Bioinformatics Shared Resource, ‖Rollins School of Public Health, and the ¶Winship Cancer Institute, Emory University, Atlanta, GA.
Theresa W Gillespie
William A Hall
Dana C Nickleach
Yuan Liu
Joseph Lipscomb
Suresh S Ramalingam
Raj S Rajpara
Seth D Force
Felix G Fernandez
Taofeek K Owonikoko
Rathi N Pillai
Fadlo R Khuri
Walter J Curran
Kristin A Higgins

Funding

Winship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Suresh S Ramalingam · 2009 to 2026
$47.5M
NCI NIH HHS P30 CA138292NCI NIH HHS P30CA138292
6 · The paper itself

Abstract

introductionUse of postoperative radiotherapy (PORT) in non-small-cell lung cancer remains controversial. Limited data indicate that PORT may benefit patients with involved N2 nodes. This study evaluates this hypothesis in a large retrospective cohort treated with chemotherapy and contemporary radiation techniques.

methodsThe National Cancer Data Base was queried for patients diagnosed 2004-2006 with resected non-small-cell lung cancer and pathologically involved N2 (pN2) nodes also treated with chemotherapy. Multivariable Cox proportional hazards model was used to assess factors associated with overall survival (OS). Inverse probability of treatment weighting (IPTW) using the propensity score was used to reduce selection bias. OS was compared between patients treated with versus without PORT using the adjusted Kaplan-Meier estimator and weighted log-rank test based on IPTW.

resultsTwo thousand and one hundred and fifteen patients were eligible for analysis. 918 (43.4%) received PORT, 1197 (56.6%) did not. PORT was associated with better OS (median survival time 42 months with PORT versus 38 months without, p = 0.048). This effect was significant in multivariable and IPTW Cox models (hazard ratio: 0.87, 95% confidence interval: 0.78-0.98, p = 0.026, and hazard ratio: 0.89, 95% confidence interval: 0.79-1.00, p = 0.046, respectively). No interaction was seen between the effects of PORT and number of involved lymph nodes (p = 0.615).

conclusionsPORT was associated with better survival for patients with pN2 nodes also treated with chemotherapy. No interaction was seen between benefit of PORT and number of involved nodes. These findings reinforce the benefit of PORT for N2 disease in modern practice using the largest, most recent cohort of chemotherapy-treated pN2 patients to date.

Indexed as

Databases, FactualAdultAgedAged, 80 and overCarcinoma, Non-Small-Cell LungCombined Modality TherapyFemaleFollow-Up StudiesHumansLung NeoplasmsLymph Node ExcisionLymph NodesMaleMiddle AgedNeoplasm GradingNeoplasms

Identifiers

PMID25384064
PMCPMC4336617

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.